Equities researchers at Stifel Nicolaus initiated coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a note issued to investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Stifel Nicolaus’ price objective points to a potential upside of 113.33% from the stock’s previous close.
Summit Therapeutics Stock Up 0.3 %
SMMT opened at $3.75 on Tuesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 9.30 and a quick ratio of 9.30. The business has a 50 day simple moving average of $4.21 and a 200-day simple moving average of $2.87. The stock has a market capitalization of $2.63 billion, a P/E ratio of -2.45 and a beta of -1.21. Summit Therapeutics has a 12 month low of $1.30 and a 12 month high of $5.22.
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.05) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.
Insider Activity
Hedge Funds Weigh In On Summit Therapeutics
Several hedge funds have recently bought and sold shares of the company. Polar Capital Holdings Plc increased its position in Summit Therapeutics by 2.5% during the first quarter. Polar Capital Holdings Plc now owns 6,272,509 shares of the company’s stock worth $15,368,000 after buying an additional 154,598 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Summit Therapeutics during the second quarter worth $49,000. Millennium Management LLC purchased a new position in Summit Therapeutics during the second quarter worth $457,000. BlackRock Inc. increased its position in Summit Therapeutics by 39.3% during the third quarter. BlackRock Inc. now owns 421,086 shares of the company’s stock worth $500,000 after buying an additional 118,878 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Summit Therapeutics during the third quarter worth $167,000. 4.61% of the stock is owned by hedge funds and other institutional investors.
Summit Therapeutics Company Profile
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Featured Articles
- Five stocks we like better than Summit Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Stock Splits, Do They Really Impact Investors?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What Are Dividend Achievers? An Introduction
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.